

Introduction. Mental health disorders and their treatments produce costs and benefits in both healthcare and non-healthcare sectors. The latter one is often referred to as inter-sectoral costs and benefits (ICBs). Limited research is available on the inclusion of these inter-sectoral costs and benefits (ICBs) in economic evaluations. In this study, we focus on the identification and classification of ICBs of mental health-related interventions within the criminal justice sector in a broader European context. This study was conducted as part of the PECUNIA-project, which aims to develop new standardized, harmonized and validated methods and tools for the assessment of costs and outcomes in European healthcare systems. The aim of the study is to further conceptualize an internationally applicable list of ICBs of mental health-related interventions in the criminal justice sector. Additionally, we aim to facilitate the inclusion of ICBs in economic evaluations across EU by prioritizing important ICBs.

Methods. Data was collected via a systematic literature search on PubMed and PsychINFO. Additionally, a grey literature search was carried out in six European countries. In order to validate the international applicability of the list and prioritize the ICBs, a survey was conducted with an international group of experts from the criminal justice sector.

Results. The literature search identified ICBs and resulted in a comprehensive list of items. A multi-dimensional list was constructed, distinguishing between costs as consequence of crime, and costs in response to crime. Based on the expert survey, the international applicability of the list was validated and the most important ICBs from the economic perspective were identified.

Conclusions. This study laid further foundations for the inclusion of important societal costs of mental health-related interventions within the criminal justice sector. More research is needed to facilitate the greater use of ICBs in economic evaluations.

OP41 Intercultural Medical Decision Support System Using Natural Language Processing (NLP)

Merve Gökgöl (mervekevser@gmail.com) and Zeynep Orhan

Introduction. This study aimed to reach patients using different languages while providing an opportunity to enter symptoms in their everyday language text besides medical expressions of symptoms.

Methodology. Named entity recognition (NER) techniques, based on natural language processing (NLP), were applied to develop a language independent predictive model. The research was based on extracting symptoms entered to the system by patient using NER method of NLP. In order to implement the system, python was used while pre-processing the data and string similarity function was used to estimate similarity with disease symptoms. Two sets were used for classification, one including only symptoms, and the other the matching diseases. Four thousand two hundred and eighty different symptoms were processed for the corresponding 880 diseases.

Results. Each user symptom had a similarity score for each symptom in all diseases. Top N results with highest similarities were

chosen from this list. The final N results are matched with diseases. According to these results, matched diseases were ordered in terms of the percentage of matched symptoms in the disease's symptoms. Extracted terms were implied as an input of the model and analysed for a matching diagnosis where an accuracy of 83 percent was accomplished when it is tested and compared using Mayo Clinic data for specific foreign languages other than English.

Conclusion. This language independent online diagnostic tool is a solution for both personal and clinical use and provides maintainable, updatable and more reliable diagnostics. This tool is particularly relevant today, with global mobility growing at a rate faster than the world's population. We aim to upgrade the system by adding speech recognition and engaging it with the background (if available, electronic health records) of the patient.

OP44 Robot-Assisted Surgery: Joint HTA To Inform Australian Policy And Funding

Paul Fennessy (paul.fennessy@dhhs.vic.gov.au), Vanessa Clements and Olivia Hibbitt

Introduction. Robot-Assisted Surgery (RAS) has been available in Australia since 2003. There are 50 da Vinci RAS systems in Australia (18 in NSW and 12 in Victoria) with most in the private hospital sector. In Australia the capital cost of a da Vinci RAS system is up to AUD 4 million (USD 2.8 million), which excludes annual maintenance fees of AUD 250,000 (USD 175,000) and consumable costs of AUD 3,500 (USD 2,450) for each procedure.

Methods. The NSW Ministry of Health and Victorian Department of Health and Human Services commissioned a health technology assessment (HTA) to explore the benefits, risks and economic implications of surgical robotics, which involved a review of the peer reviewed literature, a cost benefit analysis of public sector patients who received RAS and broad stakeholder consultation to document current perspectives on RAS applications.

Results. RAS is as safe and effective as other surgical modalities when performed by sufficiently skilled surgeons, although evidence generally comes from small studies with limited follow-up time and few studies report long term mortality, morbidity or patient-reported outcomes. Comparative benefits of RAS are uncertain as most studies conclude little or no difference in procedure related or functional outcomes. While RAS reduces length of stay, which offers patient and health system benefits, this is insufficient to fully offset high capital and consumable costs currently charged to Australian providers. Government and clinical stakeholders identified that establishing an RAS service requires consideration of important factors, including: i) Governance is critical; ii) Higher case volumes may improve financial viability; and iii) a need for state-wide/national standards for surgeon training and credentialing.

Conclusions. RAS is as safe and effective as other modalities when performed by skilled surgeons. However, uncertainty remains around long-term outcomes and clinical and cost effectiveness. An accredited training program, monitoring and evaluation will be critical to ensure outcomes data inform ongoing evidence assessment and government policy and investment.